EXAGEN INC. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Exagen reported Q2 2026 revenue of $19.9M (16% YoY growth), reduced net loss by 28% to $3.2M vs. $4.4M prior year, and narrowed adjusted EBITDA loss to $0.1M from $1.7M. The company raised full-year 2026 revenue guidance to $72–$75M from prior $70–$73M, citing record test volumes, 4% ASP growth to $446/test, and continued path toward sustainable profitability with $24.6M cash on hand.
Why this rating
Strong operational momentum—profitability inflection point within reach—but company remains loss-making. Guidance raise modest; near cash neutrality is meaningful for ~$154M market-cap biodiagnostics firm.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.